Annals of Surgical Oncology

, Volume 10, Issue 3, pp 210–212 | Cite as

Hyperthermia: Has Its Time Come?

Editorial

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    van Ruth S, Baas P, Haas RLM, Rutgers EJTh, Verwaal VJ, Zoetmulder FAN. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 2003; 10: 176–82.PubMedGoogle Scholar
  2. 2.
    McQuellon RP, Loggie BW, Lehman AB, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 2003; 10: 155–62.CrossRefPubMedGoogle Scholar
  3. 3.
    Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 1997; 63: 334–8.PubMedGoogle Scholar
  4. 4.
    Rusch VW, Niedzwiecki D, Tao Y, et al. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 1992; 10: 1001–6.PubMedGoogle Scholar
  5. 5.
    Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994; 12: 1156–63.PubMedGoogle Scholar
  6. 6.
    Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of malignancy by hyperthermia. Surg Oncol 1998; 7: 83–90.PubMedGoogle Scholar
  7. 7.
    Carry PY, Brachet A, Gilly FN, et al. A new device for the treatment of pleural malignancies: intrapleural chemohyperthermia preliminary report. Oncology 1993; 50: 348–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Ahamad A, Stevens CW, Smythe WR, et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003; 55: 768–75.PubMedGoogle Scholar
  9. 9.
    Monnet I, Breau JL, Moro D, et al. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest 2002; 121: 1921–7.PubMedGoogle Scholar
  10. 10.
    Smythe WR, Mohuiddin I, Ozveran M, Cao XX. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 2002; 123: 1191–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Ozvaran MK, Cao XX, Miller SD, Smythe WR. Antisense oligonucleotides directed at the Bcl-X gene product significantly augment chemotherapy response in mesothelioma. Paper presented at: 82nd Annual Meeting of the American Association of Thoracic Surgery; May 5–8, 2002; Washington, DC.Google Scholar
  12. 12.
    Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001; 122: 788–95.PubMedGoogle Scholar
  13. 13.
    Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single-blinded study of pemetrexed +; cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Paper presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18–21, 2002; Orlando, FL.Google Scholar
  14. 14.
    McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 2001; 27: 65–73.CrossRefPubMedGoogle Scholar
  15. 15.
    Zoetmulder FA, Verwaal VJ, Ruth S. Hyperthermic intra peritoneal chemotherapy (HIPEC) with mitomycin C significantly improves survival in patients with peritoneal carcinomatosis of colorectal origin. Paper presented at: 38th Annual Meeting of the American Society of Clinical Oncology; May 18–21, 2002; Orlando, FL.Google Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2003

Authors and Affiliations

  1. 1.Department of Surgical OncologyUniversity of Texas M. D. Anderson Cancer CenterHouston
  2. 2.Department of Surgical OncologyUniversity of Texas M. D. Anderson Cancer CenterHouston

Personalised recommendations